Skip to content

NPS Pharmaceuticals’ Orphan Drug Gattex (Teduglutide) Study Results Presented At The American College of Gastroenterology (ACG) Meeting

October 22, 2012

       NPS Pharmaceuticals’ October 22, 2012 Press Release, identifies  characteristics of 7 patients in the STEPS 2 study, who have achieved complete independence from Parenteral Nutrition (PN) and/or intravenous fluids (IV), while on orphan drug Gattex (Teduglutide).  

        A poster P1267 (found by doing a search) titled “Long-Term Therapy With Teduglutide: Characteristics of Patients With Intestinal Failure Associated With Short Bowel Syndrome Who Achieved Complete Independence From Parenteral Nutrition and/or Intravenous Fluid Support” is presented by lead study investigator Ken Fujioka, MD and colleagues, at the American College of Gastroenterology Annual Scientific Meeting in Las Vegas, Nevada.

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: